Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Institut National de la Sante Et de la Recherche Medicale |
| Country | France |
| Start Date | Jan 01, 2024 |
| End Date | Dec 31, 2028 |
| Duration | 1,826 days |
| Number of Grantees | 10 |
| Roles | Coordinator; Participant; Associated Partner; Third Party |
| Data Source | European Commission |
| Grant ID | 101137185 |
Despite the rapid development of various SARS-CoV-2 vaccines, the control of the pandemic is hampered by the constant emergence of SARS-CoV-2 variants escaping vaccine-induced immunity and the waning of immunity.
SOLVE will tackle these challenges by deciphering the mechanisms of induction of long-lasting immunity and evaluating new vaccine platforms.
To achieve this goal, an integrated plan has been developed including six pillars: 1) Vaccine discovery and design; 2) Head-to-head evaluation of the immune response and long-lasting immunity induced by four vaccine platforms in the preclinical setting; 3) Validation of the pre-clinical results in an experimental medicine trial (EMT); 4) Immune mechanisms of long-lasting immunity; 5) Data Science; 6) Determinants of population adherence to vaccination.
New immunogens including key mutations from most recent variants in RBD and Nucleocapsid sequences highly conserved across Sarbecoviruses, will be delivered through: antigen-targeting to dendritic cells (DC), i.e., CD40 DC-targeting, nanoparticles, a MVA vector and 2nd generations of mRNAs.
SOLVE will evaluate in depth the immunogenicity of these vaccines in the preclinical setting, and in an EMT testing two vaccines, i.e., CD40 DC-targeting and MVA with available GMP clinical lots. SOLVE will benefit from the most advanced technologies to identify the mechanisms of long-lasting immunity.
Integrative analyses of high throughput data, including from large cohorts, will provide insights for identification of factors (demographics, vaccines, immunity) which impact quality and longevity of immunity.
SOLVE will investigate stakeholderss perspective on the acceptability of large vaccination campaigns to improve implementation of next generation of vaccines in a preparedness track.
The consortium gathers 8 renowned public/private institutions supported by a governance facilitating fast sharing of information to keep up with a tight schedule imposed by the pandemic.
Institut National de la Sante Et de la Recherche Medicale; Commissariat A L Energie Atomique Et Aux Energies Alternatives; Centre Hospitalier Universitaire Vaudois; Agencia Estatal Consejo Superior de Investigaciones Cientificas; Universite de Bordeaux; Universite Paris Xii Val de Marne; Quantoom Biosciences; Universita Degli Studi Di Milano; Katholieke Universiteit Leuven; Eurovacc Foundation
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant